On September 4, 2026, Synergy CHC Corp., the producer of Focus Factor, registered for bankruptcy protection with the U.S. Bankruptcy Court for the District of Columbia. The filing followed a notice from Costco that it would stop selling Focus Factor products after a 16-year partnership. That one decision eliminated about 58% of Synergy’s total 2025 net revenue, set off an $18.9 million debt acceleration from its lender, and made Chapter 11 unavoidable.
A familiar pattern in the business press is on display with this filing. TheStreet reported the news, and the story about who benefits from the wreckage points to one clear name: Reckitt Benckiser, whose Neuriva brain supplement is already stocked at Costco.
The Numbers Behind the Collapse
The brand Focus Factor has a 25-year history behind it. Its products sell across the United States, Canada, and Mexico, reaching shelves at Walmart, Walgreens, Amazon, and BJ’s alike. A brain supplement with vitamins, minerals, and neuro-nutrients makes up the product line, and it holds a “#1 Pharmacist Recommended” claim tied to the 2025-2026 U.S. Pharmacy Times survey for memory support.
None of that mattered once Costco made its decision.
The SEC filing put the scale of the exposure in plain terms. “Costco accounted for approximately 58% of the Company’s net revenue during the fiscal year ended December 31, 2025,” it stated. “The Company expects Costco’s decision to have a material adverse effect on the Company’s business, results of operations, liquidity, and financial condition.”
The $18.9 million debt acceleration that followed confirmed Synergy had no financial cushion to survive even a temporary revenue disruption of this magnitude. A company that relied on one customer for more than half its sales was destroyed when that customer walked.
Reckitt’s Three Structural Advantages
Costco already sells a Reckitt Benckiser product. The Neuriva Brain Supplement Original (50 capsules) can be found there now for $43.99. Since Reckitt already has the store’s approval, it does not face the usual challenges of winning a vendor slot or meeting Costco’s famously strict supplier standards. The company is already in place, approved, integrated, and selling.
It is simple to increase the size of what an existing supplier provides, and that simplicity counts in a market where retailers keep tight control over what sits on their shelves.
Where Costco is headed, the product range fits right in. Members usually turn to wellness items that carry solid backing from well-known names and research. Reckitt has pushed Neuriva hard, adding Neuriva Plus, Neuriva Ultra, and Neuriva Memory 3D to its lineup. Those premium versions match Costco’s move toward higher-margin health solutions far more closely than the older Focus Factor offerings ever did.
The Legacy Brand’s Dark History
The FTC has settled with Focus Factor over its efficacy claims, and consumers have filed class-action suits against it. Reckitt, meanwhile, has built Neuriva’s marketing on clinically studied ingredients and GMO-free formulations.
The difference matters greatly. When a company carries a history of legal trouble, its past settlements can weigh on how customers view it again. Reckitt’s method, which rests on clinically studied ingredients and GMO-free formulas, stays free from that same weight.
Why Costco Did Not Explain Its Decision
No official explanation was offered by Costco for its decision to drop the brand. None was necessary. As a bulk retailer, Costco makes vendor decisions based on its own criteria, without feeling compelled to justify them publicly.
Synergy’s income was cut off when the decision was made, costing it roughly 58% of its 2025 net revenue in a single move. Few businesses could endure such a blow.
Reckitt’s Path Forward
According to Yahoo Finance, RBGLY is trading at $14, having declined 10.62% so far this year. The stock’s value has dropped, but the company’s underlying position remains the same. Neuriva products are already part of Reckitt’s plan with Costco’s shelves, and its product lines fit the retailer’.
Costco’s membership base naturally leans toward customers who want higher-margin health solutions, making the premium formulations a logical match for their preferences.
| Event | Date |
|---|---|
| Costco discontinues Focus Factor | July |
| Synergy files for bankruptcy | September 4, 2026 |
| Focus Factor’s revenue exposure | 58% of 2025 net revenue |
| Debt acceleration amount | $18.9 million |
Reckitt’s Clear Advantage
The company most likely to benefit from Focus Factor’s departure is Reckitt Benckiser. It already possesses the product, the pricing, and the market position needed to fill the gap left behind.
There is still more to come from this tale, yet at this point, Reckitt stands out as the obvious party gaining from it.
The Irony of It All
What makes this story ironic is that a business with a 25-year history, a #1 Pharmacist Recommended endorsement, and products sold at major retailers across North America could fall apart because of a single customer choice. Costco made no effort to justify its actions; it merely proceeded without further comment.
Costco has already accepted Reckitt’s Neuriva products, giving the company a position it did not need to compete for. They are already approved, already part of Costco’s offerings, and already being sold there. All that remains is to increase the volume of what is already proving successful.
The difference between the two companies could not be more pronounced. One staked its whole future on one customer alone. The other constructed its future from a wide array of products, relationships, and research instead. When that solitary point of failure finally gave way, the second company was already prepared.
Reckitt Benckiser stands to gain from the vacuum created by Focus Factor’s exit. The company’s Neuriva products are already on Costco’s shelves, and they align with the retailer’s push toward premium wellness solutions.
Get the Notebook.
The day's best stories and every fresh verdict, in plain English, in your inbox by seven. One email a day, no more.